HIGHFDA DRUG

Radnostix Sodium Iodide I-131 Gel Capsule Pack Recalled for 2,699 Units in 2026

Radnostix recalled 2,699 gelatin capsule packs used with its Sodium Iodide I-131 kit, distributed nationwide in the United States and Puerto Rico. The capsules failed to meet tablet/capsule specifications. Healthcare providers and patients should stop using the product and contact Radnostix for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
February 19, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
February 19, 2026
Hazard Level
HIGH
Brands
SODIUM IODIDE I-131, Radnostix, Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
SODIUM IODIDE I-131, Radnostix, Inc.
Product type
Gelatin Capsule Pack for Radiopharmaceutical Kit
Model numbers
Lot, expiry: Lot 3666245, exp: 02/28/2026, Lot 4546213, exp: 02/28/2026 and Lot 4951280, exp 09/30/2027
UPC codes
69208-000, 69208-000-00, 69208-003-15, 69208-003-25, 69208-003-35
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    February 19, 2026

  2. Reported by FDA DRUG

    April 1, 2026

  3. RecallRadar source check

    April 8, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Failed Tablet/Capsule Specifications

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Radnostix or your healthcare provider for guidance. Notification method: Letter

About This Product

Gelatin capsule packs are components used with radiopharmaceutical kits, specifically the Sodium Iodide I-131 kit. They include capsules intended for medical procedures.

Why This Is Dangerous

The failed tablet/capsule specifications may affect dosage accuracy or capsule integrity, potentially impacting treatment effectiveness or safety.

Industry Context

This recall is not identified as part of a broader industry pattern in the provided information.

Real-World Impact

No reported injuries to date. The recall requires immediate cessation of use to mitigate potential risks.

Practical Guidance

How to identify if yours is affected

  1. Check lot numbers 3666245, 4546213, 4951280 on blister cartons.
  2. Note expiry dates: 02/28/2026 for the first two lots; 09/30/2027 for Lot 4951280.

Where to find product info

Recall notices and lot/NDC details are on the FDA enforcement page linked in the recall notice. Manufacturer letters will provide next steps.

What timeline to expect

Refunds or replacements are typically processed within 4-8 weeks after the recall resolution is confirmed by the company.

If the manufacturer is unresponsive

  • Escalate to the FDA recall contact page if the company is slow to respond.
  • Consider reporting to the CPSC or FDA if you suspect a safety issue is not being addressed.

How to prevent similar issues

  • Always verify NDC and lot numbers before use.
  • Maintain awareness of recall statuses for radiopharmaceutical components.
  • When purchasing radiopharmacy kits, request official documentation and recall checks from the supplier.

Documentation advice

Retain recall letter, purchase receipts, lot/NDC numbers, and any correspondence with Radnostix or healthcare providers.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: Gelatin Capsule Pack for Sodium I-131 Kit. Contains 5 empty capsules and 5 Dibasic Sodium Phosphate capsules (300 mg). NDCs: 69208-003-15; 69208-003-25; 69208-003-35. Quantity: 2,699 blister cartons. Distributed nationwide in the US, including Puerto Rico. Sold by: Radnostix, Inc. Model numbers: Lot 3666245; Lot 4546213; Lot 4951280. Expirations: 02/28/2026 for first two lots, 09/30/2027 for Lot 4951280.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 2,699 blister cartons recalled
  • Distributed nationwide in US including Puerto Rico

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
Lot
expiry: Lot 3666245
exp: 02/28/2026
Lot 4546213
exp: 02/28/2026 and Lot 4951280
+1 more
UPC Codes
69208-000
69208-000-00
69208-003-15
+2 more
Affected States
ALL
Report Date
April 1, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

Taro Pharmaceuticals Withdraws Diclofenac Sodium Gel Over Viscosity Issues

Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.

BEEKEEPER'S NATURALS USA
Microbial Contamination
Read more
Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more